KR20100053609A - 허혈성 또는 재관류 사건에 의해 유발된 심장의 장애 또는 간접적 후유증을 치료 또는 예방하기 위한 요산 산화효소의 용도 - Google Patents

허혈성 또는 재관류 사건에 의해 유발된 심장의 장애 또는 간접적 후유증을 치료 또는 예방하기 위한 요산 산화효소의 용도 Download PDF

Info

Publication number
KR20100053609A
KR20100053609A KR1020107004878A KR20107004878A KR20100053609A KR 20100053609 A KR20100053609 A KR 20100053609A KR 1020107004878 A KR1020107004878 A KR 1020107004878A KR 20107004878 A KR20107004878 A KR 20107004878A KR 20100053609 A KR20100053609 A KR 20100053609A
Authority
KR
South Korea
Prior art keywords
uric acid
treatment
acid oxidase
ischemic
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107004878A
Other languages
English (en)
Korean (ko)
Inventor
볼프강 린츠
마티아스 셰퍼
Original Assignee
사노피-아벤티스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 filed Critical 사노피-아벤티스
Publication of KR20100053609A publication Critical patent/KR20100053609A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020107004878A 2007-09-05 2008-08-20 허혈성 또는 재관류 사건에 의해 유발된 심장의 장애 또는 간접적 후유증을 치료 또는 예방하기 위한 요산 산화효소의 용도 Ceased KR20100053609A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07291072.2 2007-09-05
EP07291072 2007-09-05
US1524007P 2007-12-20 2007-12-20
US61/015,240 2007-12-20

Publications (1)

Publication Number Publication Date
KR20100053609A true KR20100053609A (ko) 2010-05-20

Family

ID=38713162

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107004878A Ceased KR20100053609A (ko) 2007-09-05 2008-08-20 허혈성 또는 재관류 사건에 의해 유발된 심장의 장애 또는 간접적 후유증을 치료 또는 예방하기 위한 요산 산화효소의 용도

Country Status (22)

Country Link
US (1) US20100266567A1 (cg-RX-API-DMAC7.html)
EP (1) EP2197550A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011509920A (cg-RX-API-DMAC7.html)
KR (1) KR20100053609A (cg-RX-API-DMAC7.html)
CN (1) CN101801460A (cg-RX-API-DMAC7.html)
AR (1) AR068360A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008295145B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816406A2 (cg-RX-API-DMAC7.html)
CA (1) CA2697929A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008002623A1 (cg-RX-API-DMAC7.html)
CO (1) CO6260090A2 (cg-RX-API-DMAC7.html)
IL (1) IL204259A (cg-RX-API-DMAC7.html)
MA (1) MA31624B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010001976A (cg-RX-API-DMAC7.html)
MY (1) MY183770A (cg-RX-API-DMAC7.html)
NZ (1) NZ583635A (cg-RX-API-DMAC7.html)
PA (1) PA8794801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20090642A1 (cg-RX-API-DMAC7.html)
TW (1) TW200927929A (cg-RX-API-DMAC7.html)
UY (1) UY31320A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009030373A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201000774B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114972A (en) * 1990-07-30 1992-05-19 Tsuyoshi Ohnishi Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities
EP1317258B1 (en) * 2000-06-28 2009-02-11 Merck & Co., Inc. Use of allopurinol for the treatment of hypertension
AU2003275160A1 (en) * 2002-09-20 2004-04-08 Oregon Health And Science University Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries
CN102816241B (zh) * 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix
US20070197512A1 (en) * 2006-01-27 2007-08-23 Japan Tobacco Inc. Carboxylic Acid Compounds and Use Thereof

Also Published As

Publication number Publication date
RU2010112867A (ru) 2011-10-10
IL204259A (en) 2013-06-27
PE20090642A1 (es) 2009-06-18
MA31624B1 (fr) 2010-08-02
NZ583635A (en) 2011-06-30
CO6260090A2 (es) 2011-03-22
MX2010001976A (es) 2010-03-10
EP2197550A1 (en) 2010-06-23
TW200927929A (en) 2009-07-01
UY31320A1 (es) 2009-04-30
AU2008295145A1 (en) 2009-03-12
WO2009030373A1 (en) 2009-03-12
AU2008295145B2 (en) 2013-12-05
CN101801460A (zh) 2010-08-11
BRPI0816406A2 (pt) 2017-05-16
MY183770A (en) 2021-03-12
JP2011509920A (ja) 2011-03-31
US20100266567A1 (en) 2010-10-21
CL2008002623A1 (es) 2009-01-16
PA8794801A1 (es) 2009-04-23
ZA201000774B (en) 2011-04-28
CA2697929A1 (en) 2009-03-12
AR068360A1 (es) 2009-11-11

Similar Documents

Publication Publication Date Title
US8852582B2 (en) Compositions comprising glutathione reductase and oxidized glutathione
JP6262225B2 (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
EP4129321B1 (en) Compositions comprising peptide wkdeagkplvk
Chu et al. Catestatin in defense of oxidative-stress-induced apoptosis: A novel mechanism by activating the beta2 adrenergic receptor and PKB/Akt pathway in ischemic-reperfused myocardium
Belardinelli et al. Oxidative stress, endothelial function and coenzyme Q10
Alva et al. Fructose 1, 6-bisphosphate: A summary of its cytoprotective mechanism
CN116234563A (zh) 抗致病治疗方法
JP4648317B2 (ja) マロニル−CoAデカルボキシラーゼ阻害剤として有用なピペリジン化合物
RU2573943C2 (ru) Применение prdx2 и/или prdx6 для получения фармацевтической композиции для лечения или предотвращения повреждения, старения или заболевания, вызванных повышением уровня активных форм кислорода
US6090851A (en) Use of an NADPH-oxidase inhibitor in the treatment of reperfusion injury
AU2008295145B2 (en) Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
EP2988737B1 (en) Methods and compositions for treating diseases
RU2482187C2 (ru) Применение расбуриказы для лечения или профилактики расстройств или косвенных осложнений на сердце, вызванных приступами ишемии или реперфузией
HK1143771A (en) Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events
WO2016151090A1 (en) Methods and pharmaceutical compositions for the treatment of myocardial infarction
US20250235502A1 (en) Cardio-protective effect of vasoconstriction-inhibiting factor (vif)
US20230125482A1 (en) Protein kinase c modulators
JPWO1992018120A1 (ja) 虚血・再灌流組織障害及び不整脈並びに活性酸素・フリーラジカルによる肺障害の予防又は治療剤
Visokinskas et al. Use of Mildronate in geriatric patients with congestive heart failure
JPH05139992A (ja) ヒトadfを含有する臓器保護剤
WO1992018120A1 (en) Preventive or remedy for ischemia, reperfusion-induced tissue disorder and arrhythmia as well as pulmonary disorder caused by activated oxygen free radical
US20120277264A1 (en) Antithrombotic agent
Davies et al. A combination of pharmacologic preconditioning, Na+/H+ exchange inhibition and controlled reperfusion decrease left ventricular infarct size
Paramonov et al. Erysod, erythrocyte superoxide dismutase preparation: Effects on LPO processes and morphological changes in the viscera of rats with burns under conditions of delayed antishock infusion therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100304

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130819

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150121

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150414

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150121

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I